The configuration of the immunoglobulin genes in B cell chronic lymphocytic leukemia

Leukemia

Volumn 16, Issue 6, 2002, Pages 973-984

  Dyer, M J S ^a   Oscier, D G ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

BCL6 mutations; Chromosomal translocations; Chronic lymphocytic leukemia; Immunoglobulin genes; VH mutations

Indexed keywords

ANIMALS; BASE SEQUENCE; GENE REARRANGEMENT, B-LYMPHOCYTE; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, B-CELL, CHRONIC; MICE; MOLECULAR SEQUENCE DATA; MUTATION; SEQUENCE ALIGNMENT; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN; TRANSLOCATION, GENETIC;

PROTEIN BCL 11A; PROTEIN BCL 2; PROTEIN CCND2; UNCLASSIFIED DRUG;

B CELL LEUKEMIA; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 18; CHROMOSOME TRANSLOCATION 19; CHROMOSOME TRANSLOCATION 2; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE MARKER; GENE STRUCTURE; GENETIC DISORDER; HUMAN; IMMUNOGLOBULIN GENE; LEUKEMOGENESIS; MUTATIONAL ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; REVIEW;

EID: 85047699133     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402528     Document Type: Review

References (117)

1. Genomic aberrations and survival in chronic lymphocytic leukemia
2. Ever since Knudson
3. Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia
4. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia
5. B-cell neoplasia associated gene with multiple splicing (BCMS): The candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions
6. Cancer epigenetics comes of age
7. C(m)C(A/T)GG methylation: A new epigenetic mark in mammalian DNA?
8. Cytogenetic, fluorescence in situ hybridisation, and clinical evaluation of translocations with concomitant deletion at 13q14 in chronic lymphocytic leukaemia
9. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies
10. Mechanisms of chromosomal translocations in B cell lymphomas
11. Chromosome translocations in multiple myeloma
12. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy
13. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma
14. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies
15. The BCL11 gene family: Involvement of BCL11A in lymphoid malignancies
16. H-gene utilization in t(11;14) junctions: Implications for the mechanism of translocation and the origin of mantle cell lymphoma
17. Complex layers of genetic alteration in the generation of antibody diversity
18. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death
19. Immunoglobulin heavy chain enhancer is located near or in an initiation zone of chromosomal DNA replication
20. Dependence of enhancer-mediated transcription of the immunoglobulin μ gene on nuclear matrix attachment regions
21. Regulation of matrix attachment region-dependent, lymphocyte-restricted transcription through differential localization within promyelocytic leukaemia nuclear bodies
22. Elements regulating somatic hypermutation of an immunoglobulin kappa gene: Critical role for the intron enhancer/matrix attachment region
23. Non-equivalent nuclear location of immunoglobulin alleles in B lymphocytes
24. Novel control motif cluster in the IgH delta-gamma 3 interval exhibits B cell-specific enhancer function in early development
25. Unusual deletions within the immunoglobulin heavy-chain locus in acute leukemias
26. Memory B-cell persistence is independent of persisting immunizing antigen
27. Signals sustaining human immunoglobulin V gene hypermutation in isolated germinal centre B cells
28. Signals that initiate somatic hypermutation of B cells in vitro
29. Within germinal centers, isotype switching of immunoglobulin genes occurs after the onset of somatic mutation
30. Linking class-switch recombination with somatic hypermutation
31. Frequent occurrence of deletions and duplications during somatic hypermutation: Implications for oncogene translocations and heavy chain disease
32. Indirect and direct evidence for DNA double-strand breaks in hypermutating immunoglobulin genes
33. Lack of allelic exclusion in B cell chronic lymphocytic leukemia
34. Expression of Igβ (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion
35. Demethylation and the establishment of kappa allelic exclusion
36. Somatic hypermutation in normal and transformed human B cells
37. Insight into the origin and clonal history of B cell tumours as revealed by analysis of immunoglobulin variable region genes
38. Clinical relevance of immunoglobulin mutation analysis
39. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia
40. B cells of chronic lymphatic leukemia express V genes in unmutated form
41. The pathogenesis of chronic lymphocytic leukemia; analysis of the antibody repertoire
42. H genes are associated with a more aggressive form of chronic lymphocytic leukemia
43. H gene mutational status and prognosis in chronic lymphocytic leukemia
44. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia but CD38 expression may vary during the course of the disease
45. H mutation status, CD38 expression, genomic aberrations and survival in CLL
46. H gene mutation in B cell chronic lymphocytic leukemia
47. H genes is a detrimental prognostic factor in chronic lymphocytic leukemia
48. Lack of correlation between immunoglobulin somatic mutation and expression of CD38 in chronic lymphocytic leukemia
49. Analysis of immunoglobulin (IG) variable (VH) region mutational status and CD38 phenotype for B-CLL patients entered on North Central cancer chemotherapy trials group (NCCTG) clinical trials
50. The mutational status of immunoglobulin V genes is the most important prognostic factor in B-CLL
51. P53 dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation
52. H genes
53. H repertoire
54. Somatic generation of antigen-receptor diversity: A reprise
55. Analysis of the targeting of the hypermutational machinery and the impact of subsequent selection on the distribution of nucleotide changes in human VHDJH rearrangements
56. H 1-69/DP-10 rearrangements in normal human peripheral blood and chronic lymphocytic leukaemia B cells
57. H gene expression in human aging
58. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors
59. Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells
60. H genes are inherently susceptible to amino acid replacement
61. The inference of antigen selection on Ig genes
62. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia
63. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells
64. Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells
65. Aberrant rearrangements within the immunoglobulin heavy chain locus in hairy cell leukemia
66. Aberrant rearrangements of the immunoglobulin heavy chain switch region in chronic B-cell leukemia
67. Anomalous rearrangements of the immunoglobulin heavy chain genes in human leukemias support the loop-out mechanism of class switch
68. H mutations in chronic lymphocytic leukemia
69. Identification of three subgroups of B cell chronic lymphocytic leukemia based upon mutations of BCL-6 and IgV genes
70. BCL-6 mutations are associated with immunoglobulin variable heavy chain mutations in B-cell chronic lymphocytic leukemia
71. Somatic hypermutation of immunoglobulin and non-immunoglobulin genes
72. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas
73. The role of Ig beta in precursor B cell transition and allelic exclusion
74. Widespread B29 (CD79b) gene defects and loss of expression in chronic lymphocytic leukemia
75. Aberrant B cell receptor signaling from B29 (Igγ, CD79b) gene mutations of chronic lymphocytic leukemia B cells
76. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia
77. Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion
78. CmC(A/T)GG DNA methylation in mature B cell lymphoma gene silencing
79. A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia
80. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene
81. The anti-apoptosis function of BCL2 can be genetically separated from its inhibitory effect on cell cycle entry
82. Rapid molecular cloning of rearrangements of the IGHJ locus using long-distance inverse polymerase chain reaction
83. Refinement of the BCL2/immunoglobulin heavy chain fusion gene in t(14;18)(q32;q21) by polymerase chain reaction amplification for long targets
84. Characterisation of BCL2-JH rearrangements in follicular lymphoma: PCR detection of 3′ BCL2 breakpoints and evidence of a new cluster
85. Follicular lymphomas' BCL-2/IgH junctions contain templated nucleotide insertions: Novel insights into the mechanism of t(14;18) translocation
86. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia
87. Variant translocation of the bcl-2 gene to immunoglobulin lambda light chain gene in chronic lymphocytic leukemia
88. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia
89. BCL2 translocations in leukemias of mature B cells
90. Rearrangement of the 5′ cluster region of the BCL2 gene in lymphoid neoplasm: A summary of nine cases
91. Potential Z-DNA elements surround the breakpoints of chromosome translocation within the 5′ flanking region of bcl-2 gene
92. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma
93. Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia
94. CD5 expression in human B-cell populations
95. FVT-1, a novel human transcription unit affected by variant translocation t(2;18)(p11;q21) of follicular lymphoma
96. Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia
97. T(14;19)/BCL3 rearrangements in lymphoproliferative disorders: A review of 23 cases
98. BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: A molecular and cytogenetic study
99. Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-κB
100. Bcl-3 expression promotes cell survival following interleukin-4 deprivation and is controlled by AP1 and AP1-like transcription factors
101. (1) transition
102. Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice
103. Molecular cloning and characterization of the t(2;14) translocation associated with childhood chronic lymphocytic leukemia
104. Leukaemia disease genes: Large-scale cloning and pathway predictions
105. Evi9 encodes a novel zinc finger protein that physically interacts with BCL6, a known human B-cell proto-oncogene product
106. Human EVI9, a homologue of the mouse myeloid leukemia gene, is expressed in the hematopoietic progenitors and down-regulated during myeloid differentiation of HL60 cells
107. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin's lymphoma
108. Lack of somatic hypermutation of IGH genes in lymphoid malignancies with t(2;14)(p13;q32) translocation involving the BCL11A gene
109. Cyclin D2 promoter disrupted by t(12;22)(p13;q11.2) during transformation of chronic lymphocytic leukaemia to non- Hodgkin's lymphoma
110. Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development
111. Vav is required for cyclin D2 induction and proliferation of mouse B lymphocytes activated via the antigen receptor
112. Survival of leukemic B cells promoted by engagement of the antigen receptor
113. Follicular lymphoma with a novel t(14;18) breakpoint involving the immunoglobulin heavy chain switch mu region indicates an origin from germinal center B cells